What is the 13F Pro Quality Score for OTLK?

13F Pro ranks Outlook Therapeutics, Inc. (OTLK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OTLK's current score at https://13fpro.ai/research/OTLK (free sign-up required for the full ranking).

Where does 13F Pro source OTLK data?

All Outlook Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Outlook Therapeutics, Inc. files with the SEC under CIK 1649989. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OTLK in?

Outlook Therapeutics, Inc. (OTLK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OTLK research updated on 13F Pro?

OTLK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Outlook Therapeutics, Inc.(OTLK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1649989 OTLK stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $8.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

OTLK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Outlook Therapeutics, Inc. (OTLK), a Healthcare sector company. OTLK is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $8.1m in revenue. Based on the latest XBRL financial filings (Q2 2026), Outlook Therapeutics, Inc. reports net income of $-4.5M, free cash flow of $-7.8M. Top institutional holders of OTLK by reported 13-F value include ARMISTICE CAPITAL,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. OTLK trades on the Nasdaq exchange and files with the SEC under CIK 1649989. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OTLK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Outlook Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q2 2026

$-4.5M

Free Cash Flow

Q2 2026

$-7.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$1.4MFY 2025

FY21 —FY22 —FY23 —FY25 $1.4M

Net Income

-5.8% YoY

$-62.4MFY 2025

FY21 $-53.2MFY22 $-66.1MFY23 $-59.0MFY25 $-62.4M

Operating Income

-26.2% YoY

$-67.1MFY 2025

FY21 $-51.7MFY22 $-63.1MFY23 $-53.1MFY25 $-67.1M

EPS (Diluted)

+62.1% YoY

$-1.79FY 2025

FY21 $-0.35FY22 $-0.31FY23 $-4.72FY25 $-1.79

Total Assets

-42.5% YoY

$18.6MFY 2025

FY21 $22.8MFY22 $28.5MFY23 $32.3MFY25 $18.6M

Total Debt

—FY 2025

FY21 —FY22 —FY23 —FY25 —

Op. Cash Flow

-20.6% YoY

$-51.8MFY 2025

FY21 $-54.3MFY22 $-56.7MFY23 $-43.0MFY25 $-51.8M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$1.4M	—	—	—	—	$8.1M
Net Income	$-62.4M -5.8%	$-59.0M +10.7%	$-66.1M -24.2%	$-53.2M -50.9%	$-35.2M -2.1%	$-34.5M
Operating Income	$-67.1M -26.2%	$-53.1M +15.8%	$-63.1M -21.9%	$-51.7M -40.4%	$-36.8M -1.5%	$-36.3M
EPS (Diluted)	$-1.79 +62.1%	$-4.72 -1422.6%	$-0.31 +11.4%	$-0.35 +47.8%	$-0.67	—
Total Assets	$18.6M -42.5%	$32.3M +13.2%	$28.5M +25.1%	$22.8M +15.6%	$19.7M +15.2%	$17.1M
Total Debt	—	—	—	—	—	$1.08B
Operating Cash Flow	$-51.8M -20.6%	$-43.0M +24.2%	$-56.7M -4.5%	$-54.3M -70.7%	$-31.8M +1.5%	$-32.3M

AI Insight: OTLK Financial Trends

Outlook Therapeutics shows modest operational improvement in Q1 2026 with operating losses and negative cash flow narrowing, but structural profitability remains elusive.

• Operating cash flow improved to -$8M in Q1 2026 from -$15M in Q4 2025, marking best quarter since Q2 2024.

• Net loss narrowed to -$4M in Q1 2026 from -$23M in Q4 2025, first sub-$5M quarterly loss on record.

• Negative equity persists at -$29M in Q1 2026, though improved from -$84M in Q2 2024 and -$39M in Q4 2025.

⚠ No revenue reported across all periods; company cash-burning without disclosed commercial traction.

⚠ Operating losses remain persistent at -$14M in Q1 2026; improvement trajectory may depend on pipeline advancement.

AI Insight: OTLK Ratio Trends

Outlook Therapeutics shows extreme asset inefficiency, with ROA deteriorating from +79.0% in Q3 2024 to -81.4% in Q1 2026.

• ROA collapsed from 79.0% in Q3 2024 to -81.4% in Q1 2026, indicating severe profitability contraction relative to asset base.

⚠ Negative ROA in Q1 2026 suggests operating losses outweighing asset base; monitor path to profitability and cash burn.

⚠ Limited ratio visibility across margins and leverage metrics restricts full capital structure and operational efficiency assessment.

Get alerted when OTLK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Outlook Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OTLK

ARMISTICE CAPITAL, LLC
$857.8K4,168,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$405.2K1,967,160 sh
GEODE CAPITAL MANAGEMENT, LLC
$124.2K603,606 sh
GILPIN WEALTH MANAGEMENT, LLC
$123.5K600,162 sh
BlackRock, Inc.
$98.3K477,471 sh
COMMONWEALTH EQUITY SERVICES, LLC
$96.7K470,000 sh
Warberg Asset Management LLC
$56.4K275,000 sh
RENAISSANCE TECHNOLOGIES LLC
$52.5K255,157 sh
NINE MASTS CAPITAL Ltd
$47.9K232,546 sh
Connective Capital Management, LLC
$41.2K200,000 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$857.8K	4,168,000
VANGUARD CAPITAL MANAGEMENT LLC	$405.2K	1,967,160
GEODE CAPITAL MANAGEMENT, LLC	$124.2K	603,606
GILPIN WEALTH MANAGEMENT, LLC	$123.5K	600,162
BlackRock, Inc.	$98.3K	477,471
COMMONWEALTH EQUITY SERVICES, LLC	$96.7K	470,000
Warberg Asset Management LLC	$56.4K	275,000
RENAISSANCE TECHNOLOGIES LLC	$52.5K	255,157
NINE MASTS CAPITAL Ltd	$47.9K	232,546
Connective Capital Management, LLC	$41.2K	200,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OTLK on your watchlist

Track score changes the day Outlook Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OTLK a good stock to buy?

13F Pro's AI-powered analysis of Outlook Therapeutics, Inc. (OTLK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OTLK are available on the OTLK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OTLK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OTLK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Outlook Therapeutics, Inc.'s investment landscape.